Project Grant K08HL175254
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $167K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
- The federal Project Grant award, titled "ENHANCEMENT OF GENOME EDITING IN HEMATOPOIETIC STEM CELLS BY NUCLEIC ACIDS NANOPARTICLES DELIVERY OF CRISPR/CAS SYSTEM", was granted by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $486,291 award, effective February 1, 2025 through January 31, 2028, supports the development of a nucleic acid nanoparticle technology to efficiently deliver the CRISPR/Cas9 system into...
- The National Institute of Biomedical Imaging and Bioengineering awarded University of California, Berkeley $120,394 on May 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop genome editing delivery vehicles that amplify editing efficiency by enabling cells to produce and distribute CRISPR-Cas9 editing enzymes to neighboring cells in vesicles. The research addresses inefficient delivery of genome editing to cell...
- The National Heart, Lung, and Blood Institute awarded $792,498 to Trustees Of Indiana University (Indiana University Indianapolis) on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) for a Project Grant titled "Biomimetic CRISPR Nanoformulations for Targeted Gene Editing in Thalassemia and Sickle Cell Disease." The award funds development of in vivo CRISPR delivery systems using biomimetic lipid nanoparticles (LNPs) to deliver gene-editing components to...
- The National Heart, Lung, and Blood Institute awarded $1,137,435 to the University of Pennsylvania on March 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance therapeutic gene-editing approaches for cardiovascular and inherited disease. The recipient is developing and translating gene-editing therapies across three therapeutic domains. The first targets liver-centered, multiplex editing to prevent atherosclerotic cardiovascular disease through tunable...
- The National Heart Lung and Blood Institute awarded the Regents of the University of Michigan $567,166 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop tunable multi-thrombolytic nanoformulations for treating ischemic stroke with minimal hemorrhagic risk. The research addresses limitations of current thrombolytic therapy—tissue plasminogen activator (tPA) carries serious intracranial hemorrhage complications, while plasmin, a more effective...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $2,712,905 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop safe, effective, and scalable curative therapies for hemoglobinopathies including sickle cell disease, alpha-thalassemia, beta-thalassemia, and Fanconi anemia by targeting hematopoietic stem cells in vivo using antibody-directed, lipid nanoparticle delivery systems. The research strategy...
- The National Heart, Lung, and Blood Institute awarded Duke University $814,943 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop non-viral gene therapy approaches for cardiac regeneration following myocardial injury. Duke University will develop cardiac-targeted lipid nanoparticles for in vivo transfection of cardiomyocytes and adapt a cell-state sensing platform (CELLREADR) to deliver therapeutic transgenes with cell-type precision to injured...
- The National Heart, Lung, and Blood Institute awarded Regents of the University of Michigan $104,608 under the Cardiovascular Diseases Research program (CFDA 93.837) on December 16, 2026, as a Project Grant (F30HL180048). The award funds research to determine the mechanisms by which TADA2B and SKIL regulate gamma-globin expression, with the goal of developing new therapeutic approaches for beta-hemoglobinopathies including sickle cell disease and beta-thalassemia. Preliminary genome-scale CRISPR...
- The National Heart, Lung, and Blood Institute awarded Case Western Reserve University, Office of Research Administration $1,532,398 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate a gene therapy delivery platform for cardiomyopathies. The project, titled "Bait and Switch Gene Therapy for Cardiomyopathies," addresses the clinical translation barrier in adeno-associated virus (AAV) gene therapy for genetic heart diseases including...
- The Department of Health and Human Services National Institutes of Health Office of the Director awarded the University of Massachusetts Medical School $460,625 on August 1, 2026, under the Research Infrastructure Programs (CFDA 93.351) to develop lipid nanoparticle technology for simplified CRISPR/CAS9 gene editing in Caenorhabditis elegans nematodes. The funded work addresses a bottleneck in C. elegans research where microinjection of CRISPR guides limits throughput for genome-wide mutagenesis...